Economic impact analysis of optimization measures in the use of palivizumab

• Autores: P. Araque Arroyo, Ana Muñoz Serrano, Juan Carlos Valenzuela Gámez, Araceli Pérez Orihuela, Piedad López Sánchez, Ramón Garrido Palomo
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 17, Nº. 3, 2015, pág. 5
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background: The high cost of immunoprophylaxis with palivizumab (PVZ) and the controversy around its use may represent an opportunity to optimize health expenditure.

    Method: Retrospective analysis was undertaken on the use of PVZ during two respiratory syncytial virus seasons (2010-11 and 2011-12) in a 300-bed hospital.

    Children were classifed according to diagnostic subgroups􀀏 and the economic impact of an intervention by the clinical team of pediatricians and pharmacists in the 2011-12 campaign was analyzed by comparison with the 2010-2011 campaign. Intervention measures were classified in terms of the costs that could have been avoided in 2010-2011 by direct intervention (DI) and by indirect intervention (II).

    Results: During the 2011-12 season􀀏 the greatest savings (57.1%􀀈 of the total) were in the children admitted with heart disease􀀏 lung disease􀀏 or off-label indications. The cost was €32,􀀏469􀀙􀀜.9􀀜8 higher in 2010-2011 than in 2011-2012,􀀏 27%􀀈 of which could have been avoided by DI. The efficient use of vials was 0.74%􀀈 lower in 2010-2011. Out of the 2010-2011 costs that could have been avoided by DI􀀏 9􀀜4.7%􀀈 were in children starting immunization in our hospital;􀀞 32.3%􀀈 were attributable to divergence from the immunization calendar􀀏 36􀀙.6%􀀙􀀈 to non-compliance with the administration regimen,􀀏 and 31.1%􀀈 to an inappropriate number of doses for some diagnostic categories.

    Conclusions: The introduction of an action plan to optimize the hospital use of PVZ should be considered as a priority for resource management